专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO2008019160A9 METHOD FOR IDENTIFYING REFRACTIVE-INDEX FLUCTUATIONS OF A TARGET 审中-公开
标题翻译：识别目标的折射率指数波动的方法
公开(公告)号：WO2008019160A9
公开(公告)日：2008-09-25
申请号：PCT/US2007017894
申请日：2007-08-13
申请人： UNIV NORTHWESTERN , EVANSTON NORTHWESTERN HEALTHCA , BACKMAN VADIM , LIU YANG , KIM YOUNG , ROY HEMANT , GOLDBERG MICHAEL , BRAND RANDALL , PRADHAN PRABHAKAR , SUBRAMANIAN HARIHARAN
发明人： BACKMAN VADIM , LIU YANG , KIM YOUNG , ROY HEMANT , GOLDBERG MICHAEL , BRAND RANDALL , PRADHAN PRABHAKAR , SUBRAMANIAN HARIHARAN
IPC分类号： G01J3/42
CPC分类号： G01N21/49 , A61B5/0062 , A61B5/0068 , A61B5/0075 , A61B5/0084 , G01N2021/4709
摘要： Systems and methods for identifying refractive-index fluctuations of a target are described in this application. One embodiment includes identifying one or more properties of emergent light, the emergent light to be emergent from a target, and determining refractive-index fluctuations of the target based on the one or more properties of the emergent light. The determining refractive-index fluctuations further comprises determining one or more of the variance of the refractive- index fluctuations and the spatial correlation length of the refractive- index fluctuations. The determining refractive-index fluctuations further comprises determining one or more of the variance of the refractive- index fluctuations and the spatial correlation length of the refractive- index fluctuations.
摘要翻译：在本申请中描述了用于识别目标的折射率波动的系统和方法。一个实施例包括识别出射光的一个或多个属性，从目标出射的出射光，以及基于出射光的一个或多个属性来确定目标的折射率波动。确定折射率波动进一步包括确定折射率波动的方差和折射率波动的空间相关长度的一个或多个。确定折射率波动进一步包括确定折射率波动的方差和折射率波动的空间相关长度的一个或多个。

32. 发明申请

WO2007011958A2 INTRAORAL DOSAGE FORMS OF GLUCAGON 审中-公开
标题翻译： GLUCAGON的内服剂量
公开(公告)号：WO2007011958A2
公开(公告)日：2007-01-25
申请号：PCT/US2006027901
申请日：2006-07-17
申请人： EMISPHERE TECH INC , WANG NAI FANG , LIU PUCHUN , DINH STEVEN , GOLDBERG MICHAEL M , ARBIT EHUD
发明人： WANG NAI FANG , LIU PUCHUN , DINH STEVEN , GOLDBERG MICHAEL M , ARBIT EHUD
IPC分类号： A61K38/26
CPC分类号： A61K38/26 , C07K14/605
摘要： The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and glucagon. Preferably, the composition includes a therapeutically effective amount of glucagon and the delivery agent compound. The composition of the present invention facilitates the delivery of glucagon and increases its bioavailability compared to administration without the delivery agent compound.
摘要翻译：本发明提供包含至少一种递送剂化合物和胰高血糖素的组合物（例如药物组合物）。优选地，组合物包含治疗有效量的胰高血糖素和递送剂化合物。本发明的组合物有助于胰高血糖素的递送，并且与不含递送剂化合物的给药相比，其生物利用度增加。

33. 发明申请

WO2006034300A2 GREAT WALL KINASES AND USES THEREOF 审中-公开
标题翻译：伟大的墙壁动物及其用途
公开(公告)号：WO2006034300A2
公开(公告)日：2006-03-30
申请号：PCT/US2005/033717
申请日：2005-09-19
申请人： CORNELL RESEARCH FOUNDATION, INC. , GOLDBERG, Michael, L. , YU, Jiangtao
发明人： GOLDBERG, Michael, L. , YU, Jiangtao
IPC分类号： C12N9/12
CPC分类号： C12N9/12
摘要： Reagents that regulate Greatwall, a polypeptide which functions in an autoregulatory loop required to generate and maintain high maturation promoting factor levels, and reagents which bind to Greatwall are disclosed which are useful for preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, cancer.
摘要翻译：公开了调节长壁的试剂，其是在产生和维持高成熟促进因子水平所需的自动调节循环中起作用的多肽，以及结合长城的试剂，其可用于预防，改善或纠正功能障碍或疾病，包括但不限于癌症。

34. 发明申请

WO2006017541A2 ANTIDIABETIC ORAL INSULIN-BIGUANIDE COMBINATION 审中-公开
标题翻译：抗生素口服胰岛素 - 双胍组合
公开(公告)号：WO2006017541A2
公开(公告)日：2006-02-16
申请号：PCT/US2005/027499
申请日：2005-08-03
申请人： EMISPHERE TECHNOLOGIES, INC. , ARBIT, Ehud , GOLDBERG, Michael, M. , DINH, Steven
发明人： ARBIT, Ehud , GOLDBERG, Michael, M. , DINH, Steven
IPC分类号： A61K38/28
CPC分类号： A61K38/28 , A61K31/155 , A61K2300/00
摘要： Pharmaceutical dosage forms, comprising insulin, a delivery agent that facilitates insulin transport in a therapeutically effective amount to the bloodstream and a biguanide, such as metformin, are disclosed for oral administration to a patient for the treatment of diabetes. Also disclosed are methods for achieving improved glucose tolerance and glycemic control in a diabetic mammal without any statistically significant increase in weight, risk of hypoglycemia or hyperinsulinemia, and the need for monitoring blood glucose concentrations or HbA1c levels, and methods for reducing the incidence and/or severity of one or more disease states associated with chronic dosing of insulin; for prophylactically sparing (3-cell function or for preventing (3-cell death or dysfunction in a mammal with impaired glucose tolerance or early stage diabetes mellitus; and for long-term protection from developing (or delaying the onset of) overt or insulin dependent diabetes in a mammal with impaired glucose tolerance or early stage diabetes.
摘要翻译：公开了包括胰岛素，促进胰岛素以治疗有效量转运至血液的递送剂和双胍，例如二甲双胍的药物剂型，用于口服给患者治疗糖尿病。还公开了用于在糖尿病哺乳动物中实现改善的葡萄糖耐量和血糖控制的方法，而没有任何统计学上显着的重量增加，低血糖或高胰岛素血症的风险，以及监测血糖浓度或HbA1c水平的需要，以及用于降低发生率和/ 或与慢性给药胰岛素相关的一种或多种疾病状态的严重程度; 用于预防性保护（3细胞功能或用于预防（葡萄糖耐量降低或早期糖尿病）的哺乳动物中的3细胞死亡或功能障碍;以及用于长期保护以发展（或延迟发作）明显或胰岛素依赖性具有葡萄糖耐量降低或早期糖尿病的哺乳动物的糖尿病。

35. 发明申请

WO2011097148A3 USE OF ORAL HEPARIN PREPARATIONS TO TREAT URINARY TRACT DISEASES AND CONDITIONS 审中-公开
标题翻译：使用口服肝素制剂治疗尿路感染疾病和病症
公开(公告)号：WO2011097148A3
公开(公告)日：2011-09-29
申请号：PCT/US2011023108
申请日：2011-01-31
申请人： PARSONS LOWELL C , GOLDBERG MICHAEL M
发明人： PARSONS LOWELL C , GOLDBERG MICHAEL M
IPC分类号： A61K31/727
CPC分类号： A61K31/727
摘要： An improved method of treating lower urinary dysfunctional epithelium (LUDE) or a disease, condition, or syndrome associated with LUDE, including interstitial cystitis, comprises the step of administering orally a pharmaceutically effective quantity of heparin to a patient in need of treatment for LUDE or a disease, condition, or syndrome associated with LUDE in order to treat LUDE or a disease, condition, or syndrome associated with LUDE. The heparin can be administered together with a quantity of a penetration enhancer that is sufficient to result in a tissue concentration of heparin that is sufficient to treat LUDE or a disease, condition, or syndrome associated with LUDE. A suitable penetration enhancer is sodium N-[8-(2- hydroxybenzoyl)amino]caprylate. The method can further comprise the administration of at least one additional pharmaceutical composition to treat LUDE or a disease, condition, or syndrome associated with LUDE The invention further includes a pharmaceutical composition comprising: (1) a quantity of heparin that is pharmaceutically sufficient for the treatment of LUDE or a disease, condition, or syndrome associated with LUDE; and (b) at least one filler, excipient, or carrier; wherein the pharmaceutical composition is formulated for the treatment of LUDE or a disease, condition, or syndrome associated with LUDE.
摘要翻译：治疗下尿路功能障碍上皮细胞（LUDE）或与LUDE相关的疾病，病症或综合征包括间质性膀胱炎的改进方法包括向需要治疗LUDE的患者口服施用药学有效量的肝素的步骤或与LUDE相关的疾病，病症或综合征，以治疗LUDE或与LUDE相关的疾病，病症或综合征。肝素可与一定量的渗透促进剂一起施用，所述渗透促进剂足以产生足以治疗LUDE或与LUDE相关的疾病，病症或综合征的肝素组织浓度。合适的渗透促进剂是N- [8-（2-羟基苯甲酰）氨基]辛酸钠。该方法可以进一步包括施用至少一种另外的药物组合物以治疗与LUDE相关的LUDE或疾病，病症或综合征。本发明进一步包括药物组合物，其包含：（1）一定量的肝素，其对于治疗LUDE或与LUDE相关的疾病，病症或综合征; 和（b）至少一种填充剂，赋形剂或载体; 其中所述药物组合物被配制用于治疗与LUDE相关的LUDE或疾病，病症或综合征。

36. 发明申请

WO2010045408A3 AUTOMATED DELIVERY OF AEROSOLIZED DRUGS DURING ANESTHESIA WITH SYNCHRONIZED VENTILATION 审中-公开
标题翻译：通过同步通气自动输送麻醉药物
公开(公告)号：WO2010045408A3
公开(公告)日：2010-08-12
申请号：PCT/US2009060752
申请日：2009-10-15
申请人： COOPER HEALTH SYSTEM , ADAMOV VICTOR , GOLDBERG MICHAEL E , TORJMAN MARC , SAFARYN JOHN E , GRATZ IRWIN
发明人： ADAMOV VICTOR , GOLDBERG MICHAEL E , TORJMAN MARC , SAFARYN JOHN E , GRATZ IRWIN
IPC分类号： A61M11/02 , A61M16/01
CPC分类号： A61M16/01 , A61M11/00
摘要： A system for delivery of drugs to a patient while connected to a general anesthesia machine is disclosed, the system comprising (A) a breathing circuit comprising (1) an inhalation tube; (2) an exhalation tube; and (3) a connector having a first side adapted to fluidly connect with the inhalation and exhalation tubes, a second side adapted to fluidly connect with an endotracheal tube or face mask, and a special port adapted to connect with a nebulizer machine or a therapeutic vaporizor; (B) a programmable control module to regulate the timing and volume of anesthetic gases and oxygen delivered to the patient; (B) a ventilator; (C) a nebulizer machine comprising at least two interchangeable liquid or aerosolized drug containers or chambers; the nebulizer machine connected to the breathing circuit via the special port. A method of delivering drugs from a nebulizer while a patient is intubated and connected to a general anesthesia machine using the novel system is also disclosed.
摘要翻译：公开了一种在连接到全身麻醉机的情况下向患者输送药物的系统，所述系统包括（A）呼吸回路，包括（1）吸入管; （2）呼气管; 和（3）连接器，其具有适于与吸入和呼气管流体连接的第一侧，适于与气管内导管或面罩流体连接的第二侧和适于与喷雾器或治疗剂连接的特殊端口 vaporizor; （B）可编程控制模块，用于调节输送给患者的麻醉气体和氧气的时间和体积; （B）呼吸机; （C）包括至少两个可互换液体或雾化的药物容器或腔室的喷雾器; 雾化器通过专用端口连接到呼吸回路。还公开了当患者插管并连接到使用新颖系统的全身麻醉机时从喷雾器输送药物的方法。

37. 发明申请

WO2008143916A2 PROKINETIC AGENT FOR BOWEL PREPARATION 审中-公开
标题翻译： BOWEL准备工程代理
公开(公告)号：WO2008143916A2
公开(公告)日：2008-11-27
申请号：PCT/US2008006209
申请日：2008-05-15
申请人： THERAVANCE INC , KITT MICHAEL , GOLDBERG MICHAEL
发明人： KITT MICHAEL , GOLDBERG MICHAEL
IPC分类号： A61K31/4402 , A61K31/42 , A61K31/4709 , A61K31/765 , A61K45/06 , A61K49/00 , A61P1/00
CPC分类号： A61K31/4709 , A61K31/4402 , A61K31/765 , A61K33/42 , A61K45/06 , A61K2300/00
摘要： The invention provides methods of bowel preparation before a diagnostic, surgical or therapeutic procedure, in particular, bowel preparation before a colonoscopy procedure, using a 5-HT4 receptor agonist as a prokinetic agent.
摘要翻译：本发明提供在诊断，手术或治疗过程之前的肠道制备方法，特别是在结肠镜检查程序之前使用5-HT 4受体激动剂作为促动力剂的肠道制备方法。

38. 发明申请

WO2008019160A2 METHOD FOR IDENTIFYING REFRACTIVE-INDEX FLUCTUATIONS OF A TARGET 审中-公开
公开(公告)号：WO2008019160A2
公开(公告)日：2008-02-14
申请号：PCT/US2007017894
申请日：2007-08-13
申请人： UNIV NORTHWESTERN , EVANSTON NORTHWESTERN HEALTHCA , BACKMAN VADIM , LIU YANG , KIM YOUNG , ROY HEMANT , GOLDBERG MICHAEL , BRAND RANDALL , PRADHAN PRABHAKAR , SUBRAMANIAN HARIHARAN
发明人： BACKMAN VADIM , LIU YANG , KIM YOUNG , ROY HEMANT , GOLDBERG MICHAEL , BRAND RANDALL , PRADHAN PRABHAKAR , SUBRAMANIAN HARIHARAN
IPC分类号： G01J1/42
CPC分类号： G01N21/49 , A61B5/0062 , A61B5/0068 , A61B5/0075 , A61B5/0084 , G01N2021/4709
摘要： Systems and methods for identifying refractive-index fluctuations of a target are described in this application. One embodiment includes identifying one or more properties of emergent light, the emergent light to be emergent from a target, and determining refractive-index fluctuations of the target based on the one or more properties of the emergent light. The determining refractive-index fluctuations further comprises determining one or more of the variance of the refractive- index fluctuations and the spatial correlation length of the refractive- index fluctuations. The determining refractive-index fluctuations further comprises determining one or more of the variance of the refractive- index fluctuations and the spatial correlation length of the refractive- index fluctuations.

39. 发明申请

WO2004062587A2 NIGHT-TIME ORAL INSULIN THERAPY 审中-公开
标题翻译：夜间口服胰岛素治疗
公开(公告)号：WO2004062587A2
公开(公告)日：2004-07-29
申请号：PCT/US2004/000273
申请日：2004-01-06
申请人： EMISPHERE TECHNOLOGIES, INC. , GOLDBERG, Michael , ARBIT, Ehud
发明人： GOLDBERG, Michael , ARBIT, Ehud
IPC分类号： A61K
CPC分类号： A61K38/28
摘要： A method for protection of a mammal that has impaired glucose tolerance or early stage diabetes mellitus from developing overt or insulin dependent diabetes comprises administering an orally effective dose of a pharmaceutical formulation comprising insulin at nighttime, e.g., at or shortly before bedtime.
摘要翻译：保护具有葡萄糖耐量降低或糖尿病早期受损的哺乳动物从发展明显或胰岛素依赖性糖尿病的方法包括在夜间，例如在睡前或在就寝时间之前施用口服有效剂量的包含胰岛素的药物制剂。

40. 发明申请

WO03045331A3 FORMULATIONS FOR ORAL ADMINISTRATION OF CROMOLYN SODIUM 审中-公开
标题翻译： CROMOLYN SODIUM的口服药物制剂
公开(公告)号：WO03045331A3
公开(公告)日：2003-08-14
申请号：PCT/US0238247
申请日：2002-11-29
申请人： EMISPHERE TECH INC , ABBAS RICHAT , ARBIT EHUD , GOLDBERG MICHAEL , WONG VIVIAN , SARUBBI DONALD J
发明人： ABBAS RICHAT , ARBIT EHUD , GOLDBERG MICHAEL , WONG VIVIAN , SARUBBI DONALD J
IPC分类号： A61K9/10 , A61K9/20 , A61K9/48 , A61K31/352 , A61K47/16 , A61K47/18 , A61K47/20 , A61P11/02 , A61P11/06 , A61P19/02 , A61P29/00 , A61P37/02 , A61K31/40
CPC分类号： A61K31/352 , A61K9/4858 , A61K47/183
摘要： An oral dosage form comprises cromolyn sodium (sodium or disodium cromoglycate), and an acylated amino acid delivery agent.
摘要翻译：口服剂型包括色甘酸钠（色甘酸钠或二钠）和酰化氨基酸递送剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式